{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:53:09Z","timestamp":1789023189515,"version":"build-2803163510"},"reference-count":46,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013209","name":"Hellenic Foundation for Research and Innovation (HFRI)","doi-asserted-by":"publisher","award":["5553"],"award-info":[{"award-number":["5553"]}],"id":[{"id":"10.13039\/501100013209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Combination therapy with antibiotics and phages has been suggested to increase the antibacterial activity of both antibiotics and phages. We tested the in vitro activity of five antibiotics belonging to different classes in combination with lytic bacteriophages against multidrug-resistant metallo-\u03b2-lactamase (MBL)-producing Pseudomonas aeruginosa isolates. Material\/Methods: A total of 10 non-repetitive well-characterized MBL-producing P. aeruginosa isolates (5 NDM, 5 VIM) co-resistant to aminoglycosides and quinolones were used. Phage\u2013antibiotic interactions were assessed using an ISO-20776-based broth microdilution checkerboard assay in 96-well microtitration plates. Two-fold dilutions of colistin (8\u20130.125 mg\/L), ciprofloxacin, meropenem, aztreonam, and amikacin (256\u20134 mg\/L) were combined with ten-fold dilutions of five different phages (5 \u00d7 109\u20135 \u00d7 100 PFU\/mL) belonging to Pakpunavirus, Phikzvirus, Pbunavirus, and Phikmvvirus genus. Plates were incubated at 35 \u00b1 2 \u00b0C for 24 h, and the minimum inhibitory concentration of antibiotics (MICA) and phages (MICP) were determined as the lowest drug and phage concentration, resulting in &lt;10% growth based on photometric reading at 550 nm. Interactions were assessed based on the fractional inhibitory concentration index (FICi) of three independent replicates and clinical relevance based on the reversal of phenotypic resistance. The statistical significance of each drug alone and in combination with phages was assessed using GraphPad Prism 8.0. Results: Synergistic and additive interactions were found for 60\u201380% of isolates for all drugs. FICis were statistically significantly lower than 0.5 for colistin (p = 0.005), ciprofloxacin (p = 0.02), meropenem (p = 0.003), and amikacin (p = 0.002). Interactions were found at clinically achievable concentrations for colistin, meropenem, and amikacin, and a reversal of phenotypic resistance was observed for most strains (63\u201364%) for amikacin and meropenem. Antagonism was found for few isolates with all antibiotics tested. Phage vB_PaerM_AttikonH10 and vB_PaerP_AttikonH4 belonging to Phikzvirus and Phikmvvirus genus, respectively, showed either synergistic (FICi \u2264 0.35) or additive effects with most antibiotics tested. Conclusions: Synergy was observed for most drugs and phages with amikacin, showing strong synergy and reversal of phenotypic resistance against most isolates. Taking into account the wide utility of jumbo phages obtained, the findings of vB_PaerM_AttikonH10 in combination with different classes of antibiotics can enhance the activity of currently ineffective antibiotics against MBL-producing P. aeruginosa isolates.<\/jats:p>","DOI":"10.3390\/ph18030343","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T04:28:18Z","timestamp":1740716898000},"page":"343","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["In Vitro Interactions Between Bacteriophages and Antibacterial Agents of Various Classes Against Multidrug-Resistant Metallo-\u03b2-Lactamase-Producing Pseudomonas aeruginosa Clinical Isolates"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1934-8691","authenticated-orcid":false,"given":"Paschalis","family":"Paranos","sequence":"first","affiliation":[{"name":"Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Rimini 1, Haidari, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0878-5124","authenticated-orcid":false,"given":"Sophia","family":"Vourli","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Rimini 1, Haidari, 12462 Athens, Greece"},{"name":"Institute of Biosciences and Applications, National Center for Scientific Research \u201cDemokritos\u201d, Patr. Gregoriou E & 27 Neapoleos Str, 15341 Agia Paraskevi, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6298-9577","authenticated-orcid":false,"given":"Spyros","family":"Pournaras","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Rimini 1, Haidari, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8869-1509","authenticated-orcid":false,"given":"Joseph","family":"Meletiadis","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Rimini 1, Haidari, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Santamar\u00eda-Corral, G., Senhaji-Kacha, A., Broncano-Lavado, A., Esteban, J., and Garc\u00eda-Quintanilla, M. (2023). Bacteriophage\u2013Antibiotic Combination Therapy against Pseudomonas aeruginosa. Antibiotics, 12.","DOI":"10.3390\/antibiotics12071089"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and Diagnostics of Carbapenem Resistance in Gram-Negative Bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","article-title":"Global Prevalence of Cefiderocol Non-Susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: A Systematic Review and Meta-Analysis","volume":"30","author":"Karakonstantis","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e00044-24","DOI":"10.1128\/cmr.00044-24","article-title":"Pharmacokinetics and Pharmacodynamics of Bacteriophage Therapy: A Review with a Focus on Multidrug-Resistant Gram-Negative Bacterial Infections","volume":"37","author":"Siopi","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev.micro.55.1.437","article-title":"Bacteriophage Therapy","volume":"55","author":"Summers","year":"2003","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gordillo Altamirano, F.L., and Barr, J.J. (2019). Phage Therapy in the Postantibiotic Era. Clin. Microbiol. Rev., 32.","DOI":"10.1128\/CMR.00066-18"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Oechslin, F. (2018). Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy. Viruses, 10.","DOI":"10.3390\/v10070351"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"\u0141usiak-Szelachowska, M., Mi\u0119dzybrodzki, R., Drulis-Kawa, Z., Cater, K., Kne\u017eevi\u0107, P., Winogradow, C., Amaro, K., Jo\u0144czyk-Matysiak, E., Weber-D\u0105browska, B., and R\u0119kas, J. (2022). Bacteriophages and Antibiotic Interactions in Clinical Practice: What We Have Learned so Far. J. Biomed. Sci., 29.","DOI":"10.1186\/s12929-022-00806-1"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kovacs, C.J., Rapp, E.M., Rankin, W.R., McKenzie, S.M., Brasko, B.K., Hebert, K.E., Bachert, B.A., Kick, A.R., Burpo, F.J., and Barnhill, J.C. (2024). Combinations of Bacteriophage Are Efficacious against Multidrug-Resistant Pseudomonas aeruginosa and Enhance Sensitivity to Carbapenem Antibiotics. Viruses, 16.","DOI":"10.3390\/v16071000"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e00578-23","DOI":"10.1128\/aac.00578-23","article-title":"Phage-Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in in Vitro Static and Dynamic Biofilm Models","volume":"67","author":"Holger","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Manohar, P., Loh, B., Nachimuthu, R., and Leptihn, S. (2024). Phage-Antibiotic Combinations to Control Pseudomonas aeruginosa\u2013Candida Two-Species Biofilms. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-59444-2"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e00065-23","DOI":"10.1128\/iai.00065-23","article-title":"Class-Driven Synergy and Antagonism between a Pseudomonas Phage and Antibiotics","volume":"91","author":"Nicholls","year":"2023","journal-title":"Infect. Immun."},{"key":"ref_13","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2024, November 25). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 14.0. Available online: http:\/\/www.eucast.org."},{"key":"ref_14","first-page":"670","article-title":"Investigation of PhiKZ Phage Therapy against Pseudomonas aeruginosa in Mouse pneumonia Model","volume":"48","author":"Can","year":"2018","journal-title":"Turk. J. Med. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Latz, S., Kr\u00fcttgen, A., H\u00e4fner, H., Buhl, E.M., Ritter, K., and Horz, H.P. (2017). Differential Effect of Newly Isolated Phages Belonging to PB1-Like, PhiKZ-Like and LUZ24-Like Viruses against Multi-Drug Resistant Pseudomonas aeruginosa under Varying Growth Conditions. Viruses, 9.","DOI":"10.3390\/v9110315"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/B978-0-12-800098-4.00005-2","article-title":"Bacteriophages of Pseudomonas aeruginosa: Long-Term Prospects for Use in Phage Therapy","volume":"88","author":"Krylov","year":"2014","journal-title":"Adv. Virus Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12250-014-3546-3","article-title":"Selection of Phages and Conditions for the Safe Phage Therapy against Pseudomonas aeruginosa Infections","volume":"30","author":"Krylov","year":"2015","journal-title":"Virol. Sin."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Akturk, E., Pinto, G., Ostyn, L., Crabb\u00e9, A., Melo, L.D.R., Azeredo, J., and Coenye, T. (2025). Combination of Phages and Antibiotics with Enhanced Killing Efficacy against Dual-Species Bacterial Communities in a Three-Dimensional Lung Epithelial Model. Biofilm, 9.","DOI":"10.1016\/j.bioflm.2024.100245"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"198909","DOI":"10.1016\/j.virusres.2022.198909","article-title":"Antibiotics Targeting Bacterial Protein Synthesis Reduce the Lytic Activity of Bacteriophages","volume":"321","author":"Vashisth","year":"2022","journal-title":"Virus Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1208\/s12248-019-0315-0","article-title":"Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients","volume":"21","author":"Chang","year":"2019","journal-title":"AAPS J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.09.024","article-title":"Synergy of Nebulized Phage PEV20 and Ciprofloxacin Combination against Pseudomonas aeruginosa","volume":"551","author":"Lin","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lin, Y., Chang, R.Y.K., Britton, W.J., Morales, S., Kutter, E., Li, J., and Chan, H.K. (2019). Inhalable Combination Powder Formulations of Phage and Ciprofloxacin for P. aeruginosa Respiratory Infections. Eur. J. Pharm. Biopharm., 142.","DOI":"10.1016\/j.ejpb.2019.08.004"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/B978-0-12-394621-8.00020-0","article-title":"Role of Host Factors in Bacteriophage \u03a629 DNA Replication","volume":"82","author":"Salas","year":"2012","journal-title":"Adv. Virus Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/jam.15647","article-title":"Bacteriophage-Antibiotic Combination Therapy for Multidrug-Resistant Pseudomonas aeruginosa: In Vitro Synergy Testing","volume":"133","author":"Holger","year":"2022","journal-title":"J. Appl. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Davis, C.M., McCutcheon, J.G., and Dennis, J.J. (2021). Aztreonam Lysine Increases the Activity of Phages E79 and PhiKZ against Pseudomonas aeruginosa PA01. Microorganisms, 9.","DOI":"10.3390\/microorganisms9010152"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101543","DOI":"10.1016\/j.mex.2021.101543","article-title":"New and Simplified Method for Drug Combination Studies by Checkerboard Assay","volume":"8","author":"Bellio","year":"2021","journal-title":"MethodsX"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Molina, F., Menor-Flores, M., Fern\u00e1ndez, L., Vega-Rodr\u00edguez, M.A., and Garc\u00eda, P. (2022). Systematic Analysis of Putative Phage-Phage Interactions on Minimum-Sized Phage Cocktails. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-06422-1"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12250-014-3547-2","article-title":"Bacteriophage Secondary Infection","volume":"30","author":"Abedon","year":"2015","journal-title":"Virol. Sin."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ma, D., Li, L., Han, K., Wang, L., Cao, Y., Zhou, Y., Chen, H., and Wang, X. (2022). The Antagonistic Interactions between a Polyvalent Phage SaP7 and \u03b2-Lactam Antibiotics on Combined Therapies. Vet. Microbiol., 266.","DOI":"10.1016\/j.vetmic.2022.109332"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"106440","DOI":"10.1016\/j.ijantimicag.2021.106440","article-title":"In Vitro Comparative Activity of the New Beta-Lactamase Inhibitor Taniborbactam with Cefepime or Meropenem against Klebsiella Pneumoniae and Cefepime against Pseudomonas aeruginosa Metallo-Beta-Lactamase-Producing Clinical Isolates","volume":"58","author":"Meletiadis","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and Clinical Epidemiology of Carbapenem-Resistant Enterobacterales in the USA (CRACKLE-2): A Prospective Cohort Study","volume":"20","author":"Arias","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1128\/JCM.06094-11","article-title":"Multilocus Sequence Typing of Total-Genome-Sequenced Bacteria","volume":"50","author":"Larsen","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1128\/JCM.00879-06","article-title":"Phenotypic Detection of Carbapenem-Susceptible Metallo-\u03b2-Lactamase-Producing Gram-Negative Bacilli in the Clinical Laboratory","volume":"44","author":"Franklin","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1128\/JCM.02117-12","article-title":"Laboratory Detection of Enterobacteriaceae That Produce Carbapenemases","volume":"50","author":"Doyle","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_35","unstructured":"Paranos, P., Skliros, D., Zrelovs, N., Svanberga, K., Kazaks, A., Flemetakis, E., and Meletiadis, J. (2023, January 15\u201318). Isolation and Characterization of Lytic Bacteriophages against High Prevalent Greek Multidrug-Resistant Pseudomonas aeruginosa Clinical Isolates. Proceedings of the 33rd Congress of the European Society of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40121-024-01092-0","article-title":"Detection of Phage\u2019s Lytic Activity Against Carbapenemase-Producing Klebsiella pneumoniae Isolates Using a High-Throughput Microbroth Growth Inhibition Assay","volume":"14","author":"Paranos","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e00743-24","DOI":"10.1128\/jcm.00743-24","article-title":"A Single-Layer Spot Assay for Easy, Fast, and High-Throughput Quantitation of Phages against Multidrug-Resistant Gram-Negative Pathogens","volume":"62","author":"Paranos","year":"2024","journal-title":"J. Clin. Microbiol."},{"key":"ref_38","unstructured":"(2012). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, Nineth Editions (Standard No. CLSI-M07-A10)."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.01433-10","article-title":"Protein Binding: Do We Ever Learn?","volume":"55","author":"Zeitlinger","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/FTD.0000000000000572","article-title":"Pharmacokinetic Characteristics and Limited Sampling Strategies for Therapeutic Drug Monitoring of Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections","volume":"41","author":"Kim","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_41","unstructured":"European Committee on Antimicrobial Susceptibility Testing (2024, November 25). Amikacin: Rationale for the Clinical Breakpoints, Version 3.0. Available online: http:\/\/www.eucast.org."},{"key":"ref_42","unstructured":"European Committee on Antimicrobial Susceptibility Testing (2024, November 25). Meropenem: Rationale for the Clinical Breakpoints, Version 3.0. Available online: http:\/\/www.eucast.org."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1093\/jac\/dkw231","article-title":"A Review of the Pharmacokinetics and Pharmacodynamics of Aztreonam","volume":"71","author":"Ramsey","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S663","DOI":"10.1093\/ofid\/ofaa439.1481","article-title":"1298. Population Pharmacokinetics of Ceftazidime-Avibactam among Critically-Ill Patients with and without Receipt of Continuous Renal Replacement Therapy","volume":"7","author":"Kline","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e00954-17","DOI":"10.1128\/AAC.00954-17","article-title":"Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1128\/AAC.04469-14","article-title":"The Strength of Synergistic Interaction between Posaconazole and Caspofungin Depends on the Underlying Azole Resistance Mechanism of Aspergillus fumigatus","volume":"59","author":"Mavridou","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/343\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:43:48Z","timestamp":1760028228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ph18030343"],"URL":"https:\/\/doi.org\/10.3390\/ph18030343","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}